CSPC Pharmaceutical Group Ltd
HKEX:1093
CSPC Pharmaceutical Group Ltd
Interest Income Expense
CSPC Pharmaceutical Group Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Interest Income Expense
-¥139m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-92%
|
CAGR 10-Years
-13%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Interest Income Expense
¥1.1B
|
CAGR 3-Years
52%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Interest Income Expense
¥145.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Interest Income Expense
¥472.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
21%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Interest Income Expense
¥958.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Interest Income Expense
¥65.5m
|
CAGR 3-Years
41%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
CSPC Pharmaceutical Group Ltd
Glance View
CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.
See Also
What is CSPC Pharmaceutical Group Ltd's Interest Income Expense?
Interest Income Expense
-139m
CNY
Based on the financial report for Sep 30, 2024, CSPC Pharmaceutical Group Ltd's Interest Income Expense amounts to -139m CNY.
What is CSPC Pharmaceutical Group Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-13%
You don't have any saved screeners yet